References
Weinshilboum RH, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32: 651–662
Hale JP, Lilleyman JS (1991) Importance of mercaptopurine dose in lymphoblastic leukemia. Arch Dis Child 66: 462–466
Klemetsdal B, Straume B, Wist E, Aarbakke J (1993) Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population. Eur J Clin Pharmacol 44: 147–152
Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 336: 225–229
Weinshilboum RM, Raymond FA, Pazmino PA (1978) Human erythrocyte thiopurine methyltransferase; radiochemical microassay and biochemical properties. Clin Chim Acta 85: 323–333
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Capdeville, R., Mousson, B., Bax, G. et al. Interactions between 6-mercaptopurine therapy and thiopurinemethyl-transferase (TPMT) activity. Eur J Clin Pharmacol 46, 385–386 (1994). https://doi.org/10.1007/BF00194412
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00194412